Does Ozempic Reduce Alcohol Cravings? 2026 Evidence

Clinical Context: This article is reviewed by a Certified Alcohol and Drug Counsellor. It provides educational information and is not a substitute for professional medical advice.

The Side Effect Nobody Was Looking For

Yes, there is now real evidence that semaglutide, the drug in Ozempic and Wegovy, reduces heavy drinking and alcohol cravings. A trial published in The Lancet in May 2026 found that people taking it cut their heavy drinking days considerably more than people on a placebo. But no GLP-1 medication is approved in Canada, or in the United States, to treat drinking. The trials so far are small, short, and mostly done in people who also have obesity.

You might be reading this because you started a GLP-1 for your weight and noticed you stopped wanting your evening wine. Or you might be quietly looking into it for someone you love, hoping there is finally an easier way in. Here is what the research actually shows, and what it means if you are in Ontario and want help with your drinking now rather than in five years.

Does Ozempic Actually Reduce Alcohol Cravings?

In controlled trials, yes. This started as an anecdote. People on GLP-1 medications for diabetes and weight kept telling their doctors, without being asked, that they had lost interest in alcohol. The wine sat in the fridge. The craving just was not there. For a few years that was all it was, a pile of stories.

Then the trials arrived. The largest semaglutide trial so far was published in The Lancet on May 2, 2026, led by Dr. Anders Fink-Jensen at the Mental Health Centre Copenhagen. It followed 108 adults who had both alcohol use disorder and obesity for 26 weeks. Half got a weekly 2.4 mg semaglutide injection, the dose sold as Wegovy. Half got a placebo. Everyone in both groups was offered up to ten sessions of cognitive behavioural therapy.

The semaglutide group drank less. Fewer heavy drinking days, less alcohol overall, fewer drinks on the days they did drink, and lower self-reported craving. Blood markers of heavy drinking went down too, which matters because it means the result did not rest on people accurately reporting their own drinking.

How Big Was the Effect, Really?

Smaller than the headlines suggest. You will see "cuts heavy drinking by 41 percent" in a lot of coverage. Here is the fuller picture: heavy drinking days fell by 41.1 percentage points in the semaglutide group, and by 26.4 percentage points in the placebo group. The difference the drug actually added was 13.7 percentage points.

That result held up statistically, and 13.7 points is a real effect. The placebo group is the part worth looking at, though. People who got a saline injection and some therapy, in a study where somebody was paying attention to their drinking every few weeks, still cut their heavy drinking days by more than a quarter. Structure and support do a lot of the work, whatever is in the syringe.

Two other trials point the same direction. A 2025 study in JAMA Psychiatry by Hendershot and colleagues randomised 48 adults to low-dose weekly semaglutide or a placebo for nine weeks, and saw reduced craving and fewer drinks on drinking days. And in July 2026, the American Journal of Psychiatry published an eight-week trial of the pill form of semaglutide in 50 adults, run by Dr. Joseph Schacht at CU Anschutz. Heavy drinking days and everyday craving both fell, though its laboratory craving measure did not separate from placebo.

That leaves three small semaglutide trials, none longer than six months, and the biggest one enrolled only people who also had obesity. Nobody has yet shown this works the same way in a person of average weight whose only concern is their drinking. The researchers themselves say that is the next study to run.

One more result belongs in the picture, because it rarely makes the news. In 2022, a Danish team tested exenatide, an older GLP-1, in 127 people with alcohol use disorder, a larger group than any semaglutide trial since. It found no overall effect on heavy drinking. When the researchers looked more closely, the only people who benefited were the ones who also had obesity, which is the same caveat sitting under the newer findings.

Why Would a Weight Loss Drug Change How Much You Drink?

Because appetite and craving run through some of the same wiring. GLP-1 is a hormone your gut releases after you eat, and part of its job is to tell your brain that you have had enough. Drugs like semaglutide copy that signal and hold it there.

The part that surprised people is where else those signals land. There are GLP-1 receptors in the brain's reward pathway, the same circuitry that makes you want the second glass before you have finished the first. When that system gets turned down, the wanting seems to fade along with it. People on these drugs often describe it as the alcohol simply going quiet, rather than as resisting anything.

If that sounds familiar, it is close to how people describe drinking on naltrexone. The two medications reach the reward system by different routes, but the lived experience people report is similar: less pull, less negotiating with yourself, less of the drink being on your mind all afternoon.

Semaglutide vs Naltrexone: How Do They Compare?

One is promising and unproven for drinking. The other is proven, approved, and available in Ontario right now.

	Semaglutide (Ozempic, Wegovy, Rybelsus)	Naltrexone
Approved in Canada for drinking?	No. Approved for type 2 diabetes, weight management, cardiovascular risk reduction and liver disease, never for drinking	Yes. Health Canada approved for alcohol dependence
Evidence base	Three small trials, 48 to 108 people, 8 to 26 weeks	Decades of trials. A 2023 JAMA review pooled 118 studies and about 21,000 people
How you take it	Weekly injection, or a daily tablet	A tablet, taken one hour before you drink on The Sinclair Method
Common side effects	Nausea and other stomach upset, usually mild to moderate	Nausea, headache, tiredness, usually settling in the first weeks
Cost in Ontario	Roughly $80 a month for generic semaglutide, and $250 to $570 for brand Ozempic or Wegovy. Publicly covered only for type 2 diabetes, never for drinking	Low cost generic, about $2.81 a tablet. A general benefit on the Ontario Drug Benefit formulary, so no Limited Use code is needed if you have ODB coverage
Do you have to quit first?	No	No. On The Sinclair Method you keep drinking while the craving unwinds

That naltrexone evidence base is the part people underestimate. The 2023 JAMA systematic review by McPheeters and colleagues found that for roughly every 11 people treated with 50 mg of oral naltrexone, one more person avoided returning to heavy drinking than would have otherwise. If you want the head to head with the other approved option, we cover naltrexone versus acamprosate separately.

Can You Get a GLP-1 Prescribed for Drinking in Canada?

Not for drinking, no. Health Canada has authorized Ozempic for type 2 diabetes and cardiovascular risk reduction, Wegovy for weight management, and Rybelsus, the tablet, for type 2 diabetes. Alcohol use disorder is not an approved indication for any of them. No GLP-1 has been approved for treating any addiction, in Canada or the United States.

A physician can prescribe an approved drug off label, meaning for a purpose it was not approved for, when they judge it appropriate. That is legal here. But if drinking is your reason for asking, you would be paying for it entirely yourself, for a medication with far less evidence behind it than one Health Canada has already approved for exactly this.

Canadians are quick to hear about a weight loss drug and slow to hear about alcohol medication, which is part of why only about 2 percent of people with alcohol use disorder ever get prescribed anything for it. The treatment gap is not caused by a shortage of drugs. It is caused by nobody offering them.

What If You Are Already on a GLP-1 and Drinking Less?

Then you have useful information about yourself, and it is worth taking seriously. If your drinking dropped away the moment a medication turned down your reward system, that tells you the pull you had been fighting was chemistry. It was never a question of willpower. A lot of people carry years of private shame, and this one observation takes some of the weight out of it.

The practical question is what happens if you come off the GLP-1, or if your dose changes. Nobody has studied whether the drinking stays down afterwards, because the trials have not run long enough. If your relationship with alcohol was a concern before the injections started, it is reasonable to get it looked at on its own terms rather than hoping the side effect holds.

Being on a GLP-1 does not rule out naltrexone. A phase 2 trial at Johns Hopkins is registered to start testing the two together, so the combination has not been studied in people yet. What it does mean is that a prescriber needs to look at your full medication list and your health history before adding anything.

How Heal@Home Can Help

At Heal@Home, we treat drinking with the medication that has actually been approved and studied for it. You book a confidential assessment online, meet an Ontario physician or nurse practitioner who works in addiction medicine, and if it fits, they send a prescription straight to your pharmacy. No referral, no waiting list, no waiting room.

Most of our patients use The Sinclair Method, which means taking naltrexone an hour before you drink and then carrying on with your life. You do not quit first. Over weeks and months, the reward alcohol delivers gets weaker, and the wanting fades with it. If you want the mechanics, our guide to getting naltrexone in Canada walks through the whole process.

If you are on a GLP-1 already, bring that to the assessment. It is useful context, not a complication.

Hoping a GLP-1 will take care of the drinking?

There is already one that works now, approved in Canada, and you can start from home in Ontario. Book a confidential conversation with our team about whether The Sinclair Method is right for you. Contact us today or call 647-545-6751.